What is the catalog number for DPPC-d62?

The catalog number for DPPC-d62 is HY-109506S.

What sizes are available for DPPC-d62?

DPPC-d62 is available in the following size(s): 1 mg, 5 mg.

How many pack sizes does DPPC-d62 come in?

DPPC-d62 is available in 2 different pack sizes.

Is DPPC-d62 in stock?

DPPC-d62 is currently made to order / not held in immediate stock. Contact us for lead time.

Who manufactures DPPC-d62?

DPPC-d62 is manufactured by QuantiMol.

What is the estimated delivery time for DPPC-d62?

Estimated delivery time for DPPC-d62 is approximately 15 business day(s), depending on your location.

Where can I find the safety data sheet (SDS/MSDS) for DPPC-d62?

The safety data sheet for DPPC-d62 is available here: http://file.medchemexpress.com/batch_PDF/HY-109506S/DPPC-d62-SDS-MedChemExpress.pdf.

DPPC-d62

DPPC-d62 is the deuterium labeled DPPC. DPPC (129Y83) is a zwitterionic phosphoglyceride that can be used for the preparation of liposomal monolayers[1]. DPPC-liposome serves effectively as a delivery vehicle for inducing immune responses against GSL antigen in mice[2].

Product Specifications

CAS Number

25582-63-2

Product Name Alternative

129Y83-d62

UNSPSC

12352211

Target

Endogenous Metabolite; Isotope-Labeled Compounds

Type

Isotope-Labeled Compounds

Related Pathways

Metabolic Enzyme/Protease; Others

Field of Research

Others

Purity

99.0

Solubility

Ethanol : 30 mg/mL (ultrasonic; warming)

Smiles

[2H]C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C(O[C@H](COC(C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])[2H])=O)COP(OCC[N+](C)(C)C)([O-])=O)=O

Molecular Formula

C40H18D62NO8P

Molecular Weight

796.42

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Miller AD. Delivery of RNAi therapeutics: work in progress. Expert Rev Med Devices. 2013 Nov;10 (6) :781-811.|[3]Akiko Uemura, et al. Induction of immune responses against glycosphingolipid antigens: comparison of antibody responses in mice immunized with antigen associated with liposomes prepared from various phospholipids. J Vet Med Sci. 2005 Dec;67 (12) :1197-201.